Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Atlanta, GA
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Baltimore, MD
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Winston-Salem, NC
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Rapid City, SD
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Abilene, TX
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Abilene, TX
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Houston, TX
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
McAllen, TX
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
San Antonio, TX
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
The Woodlands, TX
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Miami Children's Hospital
mi
from
Miami, FL
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Emory Eye Center
mi
from
Atlanta, GA
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Emory Eye Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Oregon Health and Science University
mi
from
Portland, OR
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Medical University of South Carolina
mi
from
Charleston, SC
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Pediatric Ophthalmology, P.A.
mi
from
Dallas, TX
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Pediatric Ophthalmology, P.A.
mi
from
Dallas, TX
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Stanford University
mi
from
Palo Alto, CA
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Indiana University Medical Center
mi
from
Indianapolis, IN
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Harvard University
mi
from
Boston, MA
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Harvard University
mi
from
Boston, MA
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Duke University Eye Center
mi
from
Durham, NC
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Duke University Eye Center
mi
from
Durham, NC
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Vanderbilt University
mi
from
Nashville, TN
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated:  2/8/2018
Baylor University
mi
from
Houston, TX
Infant Aphakia Treatment Study (IATS)
Infant Aphakia Treatment Study (IATS)
Status: Enrolling
Updated: 2/8/2018
Baylor University
mi
from
Houston, TX
Click here to add this to my saved trials
Advanced Glaucoma Progression Study
Detection of Glaucoma Progression Study With Macular OCT Imaging
Status: Enrolling
Updated:  2/8/2018
UCLA Jules Stein Eye Institute
mi
from
Los Angeles, CA
Advanced Glaucoma Progression Study
Detection of Glaucoma Progression Study With Macular OCT Imaging
Status: Enrolling
Updated: 2/8/2018
UCLA Jules Stein Eye Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD
Neovascular Morphology and Persistent Disease Activity Among Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  2/8/2018
Duke Eye Center
mi
from
Durham, NC
Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD
Neovascular Morphology and Persistent Disease Activity Among Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 2/8/2018
Duke Eye Center
mi
from
Durham, NC
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Valley Retina Institute, P.A.
mi
from
McAllen, TX
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Retinal Research Institute LLC
mi
from
Phoenix, AZ
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Retinal Research Institute LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Retina Institute of California
mi
from
Arcadia, CA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Retina Institute of California
mi
from
Arcadia, CA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
California Retina Consultants
mi
from
Bakersfield, CA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
California Retina Consultants
mi
from
Bakersfield, CA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Ophthalmic Clinical Trials San Diego
mi
from
Oceanside, CA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Ophthalmic Clinical Trials San Diego
mi
from
Oceanside, CA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
California Retina Consultants
mi
from
Santa Barbara, CA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
California Retina Consultants
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Retina Consultants of Southern Colorado
mi
from
Colorado Springs, CO
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Retina Consultants of Southern Colorado
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Colorado Retina Associates
mi
from
Golden, CO
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Colorado Retina Associates
mi
from
Golden, CO
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Rand Eye Institute
mi
from
Deerfield Beach, FL
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Rand Eye Institute
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Center for Retina and Macular Disease
mi
from
Lakeland, FL
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Center for Retina and Macular Disease
mi
from
Lakeland, FL
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Retina Specialty Institute
mi
from
Pensacola, FL
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Retina Specialty Institute
mi
from
Pensacola, FL
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Southeast Retina Center, P.C.
mi
from
Augusta, GA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
University Retina
mi
from
Oak Forest, IL
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
University Retina
mi
from
Oak Forest, IL
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Illinois Retina Associates
mi
from
Oak Park, IL
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Illinois Retina Associates
mi
from
Oak Park, IL
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Midwest Eye Institute
mi
from
Indianapolis, IN
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Midwest Eye Institute
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Wolfe Eye Clinic
mi
from
West Des Moines, IA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Wolfe Eye Clinic
mi
from
West Des Moines, IA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Central Plains Eye MDs
mi
from
Wichita, KA
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Central Plains Eye MDs
mi
from
Wichita, KA
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Cumberland Valley Retina Consultants
mi
from
Hagerstown, MD
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Cumberland Valley Retina Consultants
mi
from
Hagerstown, MD
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Specialty Eye Institute
mi
from
Jackson, MI
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Specialty Eye Institute
mi
from
Jackson, MI
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Sierra Eye Associates
mi
from
Reno, NV
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Sierra Eye Associates
mi
from
Reno, NV
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
New Jersey Retina
mi
from
Edison, NJ
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
New Jersey Retina
mi
from
Edison, NJ
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Island Retina
mi
from
Shirley, NY
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Island Retina
mi
from
Shirley, NY
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Retina-Vitreous Surgeons of Central New York, PC
mi
from
Syracuse, NY
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Retina-Vitreous Surgeons of Central New York, PC
mi
from
Syracuse, NY
Click here to add this to my saved trials
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  2/8/2018
Retina Associates of Cleveland, Inc.
mi
from
Beachwood, OH
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 2/8/2018
Retina Associates of Cleveland, Inc.
mi
from
Beachwood, OH
Click here to add this to my saved trials